MedTrace Logo

Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia

NCT05205668 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2023-10-02

No results posted yet for this study

Summary

This is a phase 2a, multicenter, randomized, double-blinded, placebo controlled, dose escalation study in adult subjects with COVID-19 pneumonia. The primary objective of this study is to evaluate the overall safety of F-652 in COVID subjects in order to identify safe dose(s) for future studies with adequate patient numbers to demonstrate clinical efficacy.

Conditions

Interventions

BIOLOGICAL

F-652

IL-22 fusion protein administered intravenously

BIOLOGICAL

Placebo

Placebo administered intravenously

Sponsors & Collaborators

  • EVIVE Biotechnology

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-08
Primary Completion
2022-04-08
Completion
2023-04-08
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05205668 on ClinicalTrials.gov